SCHEMBL5213699

SCHEMBL5213699

CCO[C](Cl)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10354635 0.77
SCHEMBL23824 0.74
SCHEMBL9342116 0.72 ALDH1A1 (0.35)
Water SCHEMBL27549411 0.72
SCHEMBL342 0.72
SCHEMBL697915 0.72
SCHEMBL3110498 0.72
SCHEMBL27838562 0.72 ALDH1A1 (0.56)
SCHEMBL28031346 0.72 ALDH1A1 (0.40)
SCHEMBL4124733 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1198456-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2007-09-19 EP disclosed
US-20040186132-A1 Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED 2004-09-23 US disclosed
EP-1392655-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2004-03-03 EP disclosed
US-6696459-B1 USING HIGH AFFINITY, HIGH SELECTIVITY QUINOLINE DERIVATIVESW LIGAND PHARMACEUTICALS INC. 2004-02-24 US disclosed
EP-1382597-A2 Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS, INC. (US) 2004-01-21 EP disclosed
US-6645968-B2 E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; ABBOTT LABORATORIES 2003-11-11 US disclosed
EP-1358160-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2003-11-05 EP disclosed
EP-0800519-B1 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARM INC (US) 2003-10-22 EP disclosed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 US disclosed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 US disclosed
EP-0800519-A1 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 1997-10-15 EP disclosed
WO-1996019458-A2 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INCORPORATED (US) 1996-06-27 WO disclosed
US-5032606-A Novel fluorinated resorcinol ethers and their use as anti-allergics and anti-inflammatories CIBA-GEIGY CORPORATION (US) 1991-07-16 US disclosed
EP-0222961-B1 RESORCINOL ETHERS CIBA-GEIGY AG (CH) 1989-09-20 EP disclosed
US-4820726-A Oxaloamino substituted fluorinated resorcinol ethers and anti-allergic and anti-inflammatory use thereof CIBA-GEIGY CORPORATION (US) 1989-04-11 US disclosed
US-4670604-A Novel fluorinated resorcinol ethers CIBA-GEIGY CORPORATION (US) 1987-06-02 US disclosed
EP-0222961-A1 Resorcinol ethers CIBA-GEIGY AG (CH) 1987-05-27 EP disclosed
US-4288450-A ANTIALLERGENS CIBA-GEIGY CORPORATION (US) 1981-09-08 US disclosed
US-4221806-A ANTIALLERGENS CIBA-GEIGY CORPORATION (US) 1980-09-09 US disclosed
US-4216155-A 3-GLYCOLOYLAMINO-4-OXO-4H-1-BENZOPYRAN; ANTIALLERGENS CIBA-GEIGY CORPORATION (US) 1980-08-05 US disclosed